Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Czar Louie Gaston, Robert J Grimer, Michael F. Parry, Silvia Stacchiotti, Angelo Paolo Dei Tos, Hans Gelderblom, Stefano Ferrari, Giacomo Baldi, Robin L. Jones, Sant Chawla, Paolo Casali, Axel LeCesne, Jean Yves Blay, Sander P D Dijkstra, David M Thomas, Piotr Rutkowski

Research output: Contribution to journalArticle

Abstract

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery. The long term use and toxicity of this agent is unknown as is the proportion of patients with primary or secondary resistance. It is advised that complicated cases of GCT requiring Denosumab treatment should be referred and followed up at expert centres. Collaborative studies involving further clinical trials and rigorous data collection are strongly recommended to identify the optimum use of this drug.

Original languageEnglish
Pages (from-to)15
JournalClinical sarcoma research
Volume6
Issue number1
DOIs
Publication statusPublished - 2016

    Fingerprint

Keywords

  • Journal Article
  • Review

Cite this

Gaston, C. L., Grimer, R. J., Parry, M. F., Stacchiotti, S., Dei Tos, A. P., Gelderblom, H., Ferrari, S., Baldi, G., Jones, R. L., Chawla, S., Casali, P., LeCesne, A., Blay, J. Y., Dijkstra, S. P. D., Thomas, D. M., & Rutkowski, P. (2016). Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. Clinical sarcoma research, 6(1), 15. https://doi.org/10.1186/s13569-016-0056-0